Limits...
The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts.

Wang Y, Yang J, Liu H, Bi JR, Liu Y, Chen YY, Cao JY, Lu YJ - Onco Targets Ther (2015)

Bottom Line: Hazard ratio (HR), odds ratio (OR), and 95% confidence interval (CI) in the high OPN expression group compared with the low OPN expression group were calculated and analyzed.Primary results were summarized by using a fixed-effects model or a random-effects model.OPN overexpression tended to be associated with the presence of advanced tumor TNM stage (III and IV) (OR =2.57, 95% CI 1.61-4.11, P<0.001).

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, the Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.

ABSTRACT
In the last decade, osteopontin (OPN) was identified as one of the important proteins that promote the metastasis of tumor. However, the association between OPN overexpression and clinical outcome of non-small-cell lung cancer (NSCLC) was unclear. The purpose of this study is to investigate the role of OPN in NSCLC patients. A total of 13 studies are included to explore the relationship between the OPN elevation and the overall survival (OS) and disease-free survival (DFS) in NSCLC patients. We searched for related articles in PubMed, Web of Science, Google Scholar, and Cochrane Library databases, which were published before January 31, 2015. Hazard ratio (HR), odds ratio (OR), and 95% confidence interval (CI) in the high OPN expression group compared with the low OPN expression group were calculated and analyzed. Primary results were summarized by using a fixed-effects model or a random-effects model. The stratified analyses in subgroups were also performed. Thirteen cohort studies, which involved 1,630 patients, were included. Subgroup analyses were performed by area and test method of OPN. We found that OPN was significantly associated with poor OS (HR =2.20, 95% CI 1.71-2.83, P<0.001) and DFS (HR =2.11, 95% CI 1.62-2.74, P<0.001) in NSCLC patients. OPN overexpression tended to be associated with the presence of advanced tumor TNM stage (III and IV) (OR =2.57, 95% CI 1.61-4.11, P<0.001). The Egger's test suggested that there was no publication bias in OS studies (P=0.062) and DFS studies (P=0.740). These data indicate that OPN seems to have a significant predictive potential in estimating survival in NSCLC.

No MeSH data available.


Related in: MedlinePlus

Flow diagram of the study selection process.Abbreviations: OPN, osteopontin; NSCLC, non-small-cell lung cancer.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664515&req=5

f1-ott-8-3513: Flow diagram of the study selection process.Abbreviations: OPN, osteopontin; NSCLC, non-small-cell lung cancer.

Mentions: By the initial literature search, 163 relevant articles were identified regarding the association of OPN and NSCLC. After the careful screening process, 120 studies were excluded as they were review articles, experimental research, and studies irrelevant to the current analysis. Forty-three relevant studies were selected for detailed evaluation. Of the remaining 43 studies, 30 publications did not meet the inclusion criteria and were excluded. Finally, a total of 13 studies7,10,12,13,17–25 with 1,630 patients were included in our meta-analysis (Figure 1). Four studies were performed in People’s Republic of China,17,20,22,25 two in Japan,12,13 two in America,10,21 one in Norway,19 one in England,18 one in Italy,7 one in Germany,24 and one in Korea.23 The sample size of each study varied from 25 to 244. Seven studies used IHC, five used ELISA, and one used PCR. The quality of study was assessed by Newcastle–Ottawa quality assessment scale, whose scores ranged from 5 to 7 (median =6). The characteristic of each article included in this meta-analysis is revealed in Table 2.


The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts.

Wang Y, Yang J, Liu H, Bi JR, Liu Y, Chen YY, Cao JY, Lu YJ - Onco Targets Ther (2015)

Flow diagram of the study selection process.Abbreviations: OPN, osteopontin; NSCLC, non-small-cell lung cancer.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664515&req=5

f1-ott-8-3513: Flow diagram of the study selection process.Abbreviations: OPN, osteopontin; NSCLC, non-small-cell lung cancer.
Mentions: By the initial literature search, 163 relevant articles were identified regarding the association of OPN and NSCLC. After the careful screening process, 120 studies were excluded as they were review articles, experimental research, and studies irrelevant to the current analysis. Forty-three relevant studies were selected for detailed evaluation. Of the remaining 43 studies, 30 publications did not meet the inclusion criteria and were excluded. Finally, a total of 13 studies7,10,12,13,17–25 with 1,630 patients were included in our meta-analysis (Figure 1). Four studies were performed in People’s Republic of China,17,20,22,25 two in Japan,12,13 two in America,10,21 one in Norway,19 one in England,18 one in Italy,7 one in Germany,24 and one in Korea.23 The sample size of each study varied from 25 to 244. Seven studies used IHC, five used ELISA, and one used PCR. The quality of study was assessed by Newcastle–Ottawa quality assessment scale, whose scores ranged from 5 to 7 (median =6). The characteristic of each article included in this meta-analysis is revealed in Table 2.

Bottom Line: Hazard ratio (HR), odds ratio (OR), and 95% confidence interval (CI) in the high OPN expression group compared with the low OPN expression group were calculated and analyzed.Primary results were summarized by using a fixed-effects model or a random-effects model.OPN overexpression tended to be associated with the presence of advanced tumor TNM stage (III and IV) (OR =2.57, 95% CI 1.61-4.11, P<0.001).

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, the Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.

ABSTRACT
In the last decade, osteopontin (OPN) was identified as one of the important proteins that promote the metastasis of tumor. However, the association between OPN overexpression and clinical outcome of non-small-cell lung cancer (NSCLC) was unclear. The purpose of this study is to investigate the role of OPN in NSCLC patients. A total of 13 studies are included to explore the relationship between the OPN elevation and the overall survival (OS) and disease-free survival (DFS) in NSCLC patients. We searched for related articles in PubMed, Web of Science, Google Scholar, and Cochrane Library databases, which were published before January 31, 2015. Hazard ratio (HR), odds ratio (OR), and 95% confidence interval (CI) in the high OPN expression group compared with the low OPN expression group were calculated and analyzed. Primary results were summarized by using a fixed-effects model or a random-effects model. The stratified analyses in subgroups were also performed. Thirteen cohort studies, which involved 1,630 patients, were included. Subgroup analyses were performed by area and test method of OPN. We found that OPN was significantly associated with poor OS (HR =2.20, 95% CI 1.71-2.83, P<0.001) and DFS (HR =2.11, 95% CI 1.62-2.74, P<0.001) in NSCLC patients. OPN overexpression tended to be associated with the presence of advanced tumor TNM stage (III and IV) (OR =2.57, 95% CI 1.61-4.11, P<0.001). The Egger's test suggested that there was no publication bias in OS studies (P=0.062) and DFS studies (P=0.740). These data indicate that OPN seems to have a significant predictive potential in estimating survival in NSCLC.

No MeSH data available.


Related in: MedlinePlus